| |
|
|
| |
Acute Toxicity Study at St John's National Academy of Health Sciences, India |
|
| |
|
|
| |
An acute toxicity study on Wistar rats was done, under OECD guidelines, using a very high dose of 5 g per kg body weight. No mortality or toxicity was observed. |
|
| |
|
|
| |
No mortality was observed following the administration at a very high dose of 5g/kg body weight. Body weight, feed and water intake in all the rats were comparable with that of the control. |
|
| |
|
|
| |
Subchronic Oral Toxicity Study at Bombay College of Pharmacy, India
|
|
| |
|
|
| |
A Subchronic Toxicity Study was done in Wistar Rats, under OECD guidelines, at 90 mg per kg bodyweight, which is equivalent to the recommended human dosage of 1 gram a day. No mortality or toxicity was observed. |
|
| |
|
|
| |
Mutagenicity Study [ Ames Test ] at Intox Pvt. Ltd., India |
|
| |
|
|
| |
Mutagenicity Study by Salmonella Typhimurium reverse mutation test was carried out as per the OECD guidelines. It was concluded that the product was non-Mutagenic in all the 5 strains of Salmonella Typhimurium. |
|
| |
|
|
| |
The Toxicity studies on Slimaluma were presented at the 2006 Annual Meeting and Exposition of the American Association of Pharmaceutical Chemists in San Antonio, Texas, USA, held from 29th October to 2nd November 2006.
|
|
| |
|
|
| |
Chromosomal Aberration Study at Intox Pvt. Ltd., India
|
|
| |
|
|
| |
In-Vitro Chromosomal Aberration Study was carried out on the product as per the OECD guidelines, under GLP conditions. It was concluded that the product was non-Clastogenic in the in-vitro chromosomal aberration test.
|
|
| |
|
|
| |
Teratogenicity Study at Intox Pvt. Ltd., India
|
|
| |
|
|
| |
Teratogencity Study [ Prenatal Developmental Toxicity Study ] was carried out on the product as per OECD guidelines, under GLP conditions. It was concluded that the product is non - Teratogenic in nature |
|
| |
|
|
| |
Chronic Toxicity Study at Intox Pvt. Ltd., India |
|
| |
Chronic Toxicity Study was conducted on the product to determine toxicity over long term usage, as per OECD guidelines, under GLP conditions.The study showed that the NOEL [ No Observed Effect Level ] for the product, following oral administration for 6 months was greater than 1000 mg / kg body weight, demonstrating a very high level of safety.
|
|
| |
|
|
| |
|
|
